Biopharma Should Copy Our Gilead Deal, Says Rising Star Galapagos
‘Standstill’ Guarantees Biotech’s Independence
$5.1bn alliance is most eyecatching deal of the year – but is only a start for Gilead's rebuilding program.
You may also be interested in...
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
2019 has seen European biotech companies making waves in the US IPO space. Genmab’s listing was a blockbuster, but many more companies have proven their ability to go public on the NASDAQ.
AbbVie now has both of its Humira successors approved in the US, following April’s Skyrizi approval for psoriasis. But Rinvoq faces stiff competition both within the JAK1 class and in rheumatoid arthritis generally.